Skip to main content

Nanobac Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/14/2021 08:27 PM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume100 shs
Average Volume644,245 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NNBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobac Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.


No headlines for this company have been tracked by

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:NNBP
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1964th out of 2,042 stocks

Pharmaceutical Preparations Industry

757th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nanobac Pharmaceuticals (OTCMKTS:NNBP) Frequently Asked Questions

What stocks does MarketBeat like better than Nanobac Pharmaceuticals?

Wall Street analysts have given Nanobac Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nanobac Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Nanobac Pharmaceuticals' key executives?

Nanobac Pharmaceuticals' management team includes the following people:
  • Mr. John M. Stanton, Chairman, CEO, CFO & Principal Accounting Officer (Age 58)
  • Mr. Benedict Salvadore Maniscalco, Director of Clinical Research, Medical Director & Director (Age 79, Pay $87.5k)
  • Dr. Neva Ciftcioglu, Co-Founder, Director of Science & Scientific Advisor
  • Dr. E. Olavi Kajander, Chief Science & Research Officer and MD of Nanobac OY

Who are some of Nanobac Pharmaceuticals' key competitors?

What is Nanobac Pharmaceuticals' stock symbol?

Nanobac Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NNBP."

How do I buy shares of Nanobac Pharmaceuticals?

Shares of NNBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nanobac Pharmaceuticals' stock price today?

One share of NNBP stock can currently be purchased for approximately $0.00.

How many employees does Nanobac Pharmaceuticals have?

Nanobac Pharmaceuticals employs 1 workers across the globe.

What is Nanobac Pharmaceuticals' official website?

The official website for Nanobac Pharmaceuticals is

Where are Nanobac Pharmaceuticals' headquarters?

Nanobac Pharmaceuticals is headquartered at 2727 W MARTIN LUTHER KING BLVD STE 850, TAMPA FL, 33607.

How can I contact Nanobac Pharmaceuticals?

Nanobac Pharmaceuticals' mailing address is 2727 W MARTIN LUTHER KING BLVD STE 850, TAMPA FL, 33607. The company can be reached via phone at 813-865-1125.

This page was last updated on 5/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.